Your shopping cart is currently empty

Zegocractin (CM-4620) is an inhibitor of calcium-release activated calcium (CRAC) channels.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $128 | In Stock | In Stock | |
| 5 mg | $272 | In Stock | In Stock | |
| 10 mg | $455 | In Stock | In Stock | |
| 25 mg | $753 | In Stock | In Stock | |
| 50 mg | $1,050 | In Stock | In Stock | |
| 100 mg | $1,420 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $297 | In Stock | In Stock |
| Description | Zegocractin (CM-4620) is an inhibitor of calcium-release activated calcium (CRAC) channels. |
| Targets&IC50 | Orai2/STIM1:119 nM, Orai2/STIM1:895 nM |
| In vitro | CM-4620 (compound 1) is more potent on Orai1 than Orai2-type CRAC channels. In human PBMCs, CM-4620 potently inhibits release of multiple cytokines which play important roles in T cells (IC50s, IFN γ: 138 nM, IL-6: 135 nM, IL-4: 879 nM, IL-1β: 240 nM, IL-10: 303 nM, IL-2: 59 nM, TNFα: 225 nM, IL-17 120 nM) [1]. |
| In vivo | Mouse PACs are treated with CRAC inhibitors GSK-7975A or CM-4620 and monitored for their rate of Calcium uptake. Both CRAC inhibitors reduce the rate of store-operated Calcium entry into the ER to 50% of control levels upon treatment with 700 nM of inhibitor. CM-4620 blocks 100% of the reuptake at 10 mM. |
| Synonyms | N-(5-(6-Chloro-2,2-difluorobenzo[d][1,3]dioxol-5-yl)pyrazin-2-yl)-2-fluoro-6-methylbenzamide, CM-4620, CM4620 |
| Molecular Weight | 421.76 |
| Formula | C19H11ClF3N3O3 |
| Cas No. | 1713240-67-5 |
| Smiles | Cc1cccc(F)c1C(=O)Nc1cnc(cn1)-c1cc2OC(F)(F)Oc2cc1Cl |
| Relative Density. | 1.58 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | H2O: Insoluble DMSO: 140 mg/mL (331.94 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+90% Corn Oil: 3.3 mg/mL (7.82 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.